Yang S, Zhang W, Chen Q, et al. - In advanced non-small cell lung cancer, researchers aimed at determining the clinical efficacy and safety of anlotinib with immunotherapy as third-line therapy. Among 101 evaluated patients who were diagnosed with advanced non-small cell lung cancer and were treated with anlotinib combined with immunotherapy, 19 had partial response (18.8%), 61 had stable disease (60.4%), 31 had progressive disease (20.8%). No patients achieved complete response. The Eastern Cooperative Oncology Group performance status score, smoking history, and age were identified as predictive indicators for anlotinib treatment efficacy in Cox regression analysis. Overall findings establish anlotinib combined with immunotherapy to be clinically effective in advanced non-small cell lung cancer as third-line therapy.